Podcasts about diabetes and endocrinology

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Nadia Merchant, MD Guest: Melody Shi, MD Guest: Despoina Galetaki, MD Steroids are one of the main treatments for patients with Duchenne muscular dystrophy (DMD), but prolonged steroid use can come with many endocrine side effects, like weight gain, insulin resistance, and adrenal insufficiency. To learn more about these endocrine complications and surveillance, a recent survey was conducted, and here to share the results with Dr. Charles Turck are study authors Drs. Nadia Merchant, Melody Shi, and Despoina Galetaki.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Ian de Boer, MD Since up to 40 percent of patients with diabetes develop diabetic kidney disease, it's essential to know how to proactively diagnose and treat them using the latest therapeutic advances and strategies. Tune in to hear Dr. Mary Katherine Cheeley discuss diabetes management in patients with chronic kidney disease with Dr. Ian de Boer, Professor of Medicine in the Division of Nephrology and the Director of the Kidney Research Institute at the University of Washington in Seattle.

Guest: Elena Toschi, MD Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clinician should personalize and devise the best approach to diabetes management and glycemic targets, as well as manage comorbidities and complications. To learn more, join Dr. Elena Toschi, Director of the Young Adult Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School.

CME credits: 0.75 Valid until: 20-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/plozasiran-aro-apoc3-decreases-apoc3-and-triglycerides-tg-in-patients-with-mixed-hyperlipidemia-muir-final-results/24409/ This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.

Host: John Buse, MD, PhD Guest: Kim Boggess, MD The most common forms of diabetes encountered in pregnant patients include gestational diabetes and preexisting type 2 diabetes. So how does adding metformin to insulin treatment help these patients? Join Dr. John Buse as he talks about the MOMPOD Trial with lead author, Dr. Kim Boggess, Professor of Maternal Fetal Medicine at the University of North Carolina at Chapel Hill.

Guest: R. Paul Wadwa, M.D. Since young kids have a different activity level and diet than older kids or adult patients, controlling type 1 diabetes in younger patients can be more challenging, and there tends to be more variability in their blood sugars. However, a recent study identified that hybrid closed-loop technology could help give children with type 1 diabetes the best outcomes and quality of life. To learn more, tune in with Dr. Paul Wadwa, Professor of Pediatrics and the Medical Director of the Pediatric Clinic at the Barbara Davis Center for Diabetes at University of Colorado Anschutz Medical Campus.

Host: Carol Wysham, MD Guest: A. Michael Lincoff, MD Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.

Host: John Buse, MD, PhD Guest: Louis J. Aronne, MD, FTOS In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study's findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.

CME credits: 0.50 Valid until: 20-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/revolutionizing-care-for-patients-with-t2d-and-obesity-from-pathophysiology-to-personalized-treatments/16467/ Embark on a transformative journey to redefine patient care for individuals with type 2 diabetes by transitioning from the conventional focus on glycemic control to a pioneering obesity-centered approach. Immerse yourself in the expertise of 3 distinguished professionals: Drs. Carol Wysham, Scott Kahan, and Ken Fujioka. These esteemed experts will guide you through the dynamic terrain of weight loss medications, including GLP-1/GIP dual receptor agonists, and provide invaluable insights to elevate and optimize patient outcomes in the realm of type 2 diabetes management. =

Host: John Buse, MD, PhD Guest: Mary de Groot, PhD The prevalence of diabetes-related stigma is alarmingly high. In fact, four in five adults have reported experiencing some form of diabetes stigma at some point in their lives. To learn how we as healthcare providers can help reduce this burden for our patients with diabetes, Dr. John Buse speaks with Dr. Mary de Groot, Professor of Medicine and the Associate Vice Chair for Wellness at Indiana University School of Medicine.

Host: Stuart Weinzimer, MD The artificial pancreas represents the integration of two separate devices: a continuous glucose monitor and an insulin pump. Learn more about this technology and how it can help improve diabetic patients' quality of life with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: Stuart Weinzimer, MD From continuous glocuose monitors to insulin pumps, there have been immense technological advancements for patients with type 1 diabetes. Learn more about how these two tools can be used to treat pediatric patients with type 1 diabetes with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: John Buse, MD, PhD Guest: Michael Fang, PhD According to a recent study published in the Annals of Internal Medicine, the median age of patients with type 1 diabetes is 24. However, type 1 diabetes that develops in adulthood is often mistakenly identified as type 2 diabetes, resulting in improper treatment. Joining Dr. John Buse to review this study's key findings and how we can determine if an adult with new-onset diabetes might have type 1 diabetes is Dr. Michael Fang, Assistant Professor in the Division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University.

Host: John Buse, MD, PhD Guest: Maria Jose Redondo, MD, PhD, MPH A recent paper focused on a variety of topics associated with type 1 diabetes, including its heterogenenity, endotypes, slowly progressive insulin-dependent diabetes, and the term type 1.5 diabetes. Dive into these topics with Dr. John Buse and Dr. Maria Redondo, Professor of Pediatrics in the Division of Pediatric Diabetes and Endocrinology at Baylor College of Medicine in Texas.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: David Selzer, MD New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this is Dr. David Selzer, Clinical Instructor of Medicine at NYU Grossman School of Medicine and leads the Medical Weight Loss Program at NYU Langone Medical Associates in the Florida Division.

Host: John Buse, MD, PhD Guest: Helen Murphy, PhD There are many challenges associated with managing type 1 diabetes (T1D) in pregnant patients, which is why a recent study examined the use of an automated insulin delivery system in this patient population. Using this method, insulin doses were adjusted every 8 to 10 minutes according to a patient's real-time glucose levels taken from her continuous glucose monitor. As a result, women experienced a higher percentage time in the pregnancy glucose target range, less hyperglycemia, and less gestational weight gain. Learn more about how these findings may impact the management of T1D both during and after pregnancy with Dr. John Buse and Dr. Helen Murphy, a Professor of Medicine in Diabetes and Antenatal Care at the University of East Anglia in the United Kingdom.

Host: John Buse, MD, PhD Guest: Beth Pyatak, PhD, OTR/L According to a recent study, fluncuations in glucose levels while sleeping can directly impact type 1 diabetes patients' ability to complete daily activities. In fact, it was found that higher variability overnight led to lower sustained attention and lower engagement in demanding activities the following day. So how can we control glucose levels to help our patients feel better? Explore the study's key findings and management strategies with Dr. John Buse and Dr. Elizabeth Pyatak, an Associate Professor of Occupational Science and Occupational Therapy at the University of Southern California who worked on the study.

Host: John Buse, MD, PhD Guest: Simon Heller, MD Amid the crisis around the cost of diabetes care worldwide, biosimilar insulins could help save millions of dollars and allow more patients to be treated safely and effectively. But how exactly are these products approved, and how do they compare to the original product? Find out with Dr. John Buse and Dr. Simon Heller, Professor of Clinical Diabetes at the University of Sheffield and the Director of Research and Development at Sheffield Teaching Hospitals Foundation Trust in the United Kingdom. Together, they'll review Dr. Heller's recent paper on biosimilar basal insulins that was published in Clinical Diabetes.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Elizabeth Cook, PharmD, AE-C, BCACP, CDCES With a shortage of insulin products in the United States, our diabetic patients are left without lifesaving medications, making this a prominent barrier in clinical practice. However, insulin biosimilars may offer more accessibility and affordability, but what do we know about them? Join Dr. Mary Katherine Cheeley as she speaks with Dr. Lizzie Cook, Clinical Pharmacist at Robert J. Dole Veteran Affairs Medical Center in Wichita, Kansas.

Host: John Buse, MD, PhD Guest: Jean-Philippe Drouin-Chartier, DtP, PhD What's the relationship between ultra-processed food consumption and the risk of developing type 2 diabetes? Find out with Dr. John Buse as he speaks with Dr. Jean-Philippe Drouin-Chartier about his research that sought to answer this exact question. Dr. Drouin-Chartier is an Assistant Professor at the Faculté de Pharmacie at Laval University and a researcher in the Nutrition, Health, and Society Center of the Institute on Nutrition and Functional Foods in Quebec, Canada.

CME credits: 0.50 Valid until: 18-10-2024 Claim your CME credit at https://reachmd.com/programs/cme/a-practical-look-at-cardiorenal-protection-for-ckd-in-t2d-applying-recent-data/14594/ Optimal treatment with guideline-directed therapies, including RAS inhibitors, SGLT2 inhibitors, and nonsteroidal MRAs, is paramount in preventing progressive renal dysfunction and cardiorenal events in patients with chronic kidney disease and type 2 diabetes. As the patient becomes more complex, a multidisciplinary approach is often necessary to improve their outcomes. Listen in as our panel of experts offers strategies to improve collaboration and patient care.=

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Charlton, MD Liver disease is highly prevalent in patients with type 2 diabetes, and it's much more likely to be a clinically significant issue in these patients as well. So it's important to evaluate patients for liver disease during routine check-ups. Dive further into the effects of liver disease in diabetic care with Dr. Peter Buch as he speaks with Dr. Michael Charlton, Professor of Medicine and Co-Director of the Transplant Institute at the University of Chicago.

Host: John Buse, MD, PhD Guest: David Cherney, MD, PhD There have been several major advances regarding the management of chronic kidney disease in patients with type 2 diabetes over the last 5 years, leading Dr. David Cherney and a team of authors to publish a narrative review on how to best manage these patients using the latest treatment options like SGLT2 inhibitors and non-steroidal MRAs. Tune in to hear him share key highlights from the review with Dr. John Buse. Dr. Cherney is a Professor of Medicine at the University of Toronto and the Director of the Renal Physiology Laboratory at University Health Network in Canada.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Javed Butler, MD, MBA, MPH The STEP-HFpEF study was a program of two sister trials. The study that you'll hear about today is in heart failure with preserved ejection fraction (HFpEF) and obesity patients without type 2 diabetes. Learn more about semaglutide with Dr. Mary Katherine Cheeley as she speaks with fellow ReachMD host, Dr. Javed Butler, President of Baylor Scott and White Research Institute in Dallas, Texas.

Host: John Buse, MD, PhD Guest: Louis Philipson, MD, PhD Over the last 15 years, the monogenic diabetes registry now has over 4,000 patients involved, and from that, the RADIANT study was started to identify new kinds of rare and atypical diabetes. So how can genetics testing and the RADIANT study provide atypical diabetes patients with better diagnoses and treatment? Learn more with Dr. John Buse and Dr. Louis Philipson, Professor in the Department of Medicine and Pediatrics at the University of Chicago.

Host: John Buse, MD, PhD Guest: David Simmons, MD Gestational hypertension is more common in preeclampsia, and there's more chance of the baby ending up in the neonatal intensive care unit. So what can we learn from the randomized trials of women patients with gestational diabetes? Learn more with Dr. John Buse as he speaks with Dr. David Simmons, Distinguished Professor of Medicine at the Western Sydney University Macarthur Clinical School in Australia.

CME credits: 1.00 Valid until: 30-08-2024 Claim your CME credit at https://reachmd.com/programs/cme/addressing-patient-management-in-ascvd-risk-reduction-a-collaborative-approach-broadcast-replay/15310/ We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborative approach to addressing residual cardiovascular risk across a variety of risk factors that goes beyond LDL-C-lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients will benefit from a review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you're keeping up with the science and giving your patients the best care.=

Host: John Buse, MD, PhD Guest: Karen D. Corbin, PhD, RD One of the biggest missing links in current literature about obesity and the gut microbiome was causality. In an effort to address that gap, a recent clinical trial was conducted, and now, the results are in. So what were the key findings, and how can we translate those findings into clinical practice? Find out how one's diet can affect the gut microbiome with Dr. John Buse and Dr. Karen Corbin, an Investigator at the AdventHealth Translational Research Institute in Orlando, Florida.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Suijit Janardhan, MD, PhD Diabetic patients have a significant risk for developing more advanced liver disease, and the disease that they're particularly at risk for is steatotic liver disease. Dive into this episode to learn more with Dr. Charles Turck and Dr. Sujit Janardhan, Assistant Professor in the Department of Internal Medicine, Division of Digestive Diseases and Nutrition, and the Department of Transplant Surgery at Rush University Medical Center in Chicago.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Suijit Janardhan, MD, PhD Diabetic patients have a significant risk for developing more advanced liver disease, and the disease that they're particularly at risk for is steatotic liver disease. Dive into this episode to learn more with Dr. Charles Turck and Dr. Sujit Janardhan, Assistant Professor in the Department of Internal Medicine, Division of Digestive Diseases and Nutrition, and the Department of Transplant Surgery at Rush University Medical Center in Chicago.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Suijit Janardhan, MD, PhD Diabetic patients have a significant risk for developing more advanced liver disease, and the disease that they're particularly at risk for is steatotic liver disease. Dive into this episode to learn more with Dr. Charles Turck and Dr. Sujit Janardhan, Assistant Professor in the Department of Internal Medicine, Division of Digestive Diseases and Nutrition, and the Department of Transplant Surgery at Rush University Medical Center in Chicago.

Host: John Buse, MD, PhD Guest: Anna Kahkoska, MD, PhD Continuous glucose monitoring (CGM) can help improve glycemic management in patients with type 1 diabetes (T1D), but integrating this technology can be a complex learning process for older adults. So what do we need to consider when it comes to CGM use in older adults? Find out with Dr. John Buse and Dr. Anna Kahkoska, Assistant Professor in the Department of Nutrition and an Adjunct Assistant Professor in the Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill. Dr. Kahkoska is also the author of a recent paper, titled “Nothing is linear: Characterizing the determinants and dynamics of CGM use in older adults with type 1 diabetes.”

CME credits: 0.25 Valid until: 06-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/strategies-to-reduce-treatment-burden-for-vulnerable-patients-with-diabetic-eye-disease/15355/ Vision loss due to diabetes is preventable, yet minority patients and patients of low socioeconomic status remain at a disproportionate risk of poor outcomes. Find out what Dr. Pradeep Prasad and Dr. Charles Vega are doing to curb the negative outcomes of diabetic eye disease in their patients at high risk for vision loss.=

CME credits: 0.25 Valid until: 06-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-barriers-for-vulnerable-patients-with-diabetic-eye-disease/15347/ New treatments are available to manage diabetic macular edema (DME) that have the added benefit of reducing treatment burden. This can level the playing field and benefit patients who are less likely to access routine healthcare. Tune in to hear Dr. Sharon Solomon and Dr. Charles Vega discuss how the latest clinical data measure up by prolonging treatment intervals and how retina specialists are now better equipped to care for their most vulnerable patients with DME.=

Host: John Buse, MD, PhD Guest: Anastassios Pittas, MD, MS Vitamin D has numerous benefits, and according to a recent study, it can even help reduce the risk of type 2 diabetes in patients with prediabtes. Learn more about the key findings from this research with Dr. John Buse and Dr. Anastassios Pittas, Professor of Medicine and Chief of Endocrinology at Tufts Medical Center.

Host: John Buse, MD, PhD Guest: Viral Shah, MD Severe hypoglycemia can lead to dangerous challenges, one of them being an increase in vehicular accidents. Dive into the results from a study that investigated the correlation between the prevalence of hypoglycemia while driving in adults with type 1 diabetes (T1D) and how many of those cases might have led to vehicular accidents with Dr. John Buse and Dr. Viral Shah, Associate Professor of Medicine and Pediatrics at the Barbara Davis Center for Diabetes.

CME credits: 0.25 Valid until: 26-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/examining-disparities-in-diabetic-eye-health/15346/ Racial and ethnic minorities are disproportionately affected by diabetic eye disease, which is one of the leading causes of vision loss in the United States. Hear how Dr. Ruth Shoge and Dr. Charles Vega are approaching patient care and find out what tools are available to you. Join us in overcoming barriers to vision care so that all patients can receive the treatment they need.=

Host: John Buse, MD, PhD Guest: Steven Nissen, MD Among statin-intolerant patients, treatment with bempedoic acid is associated with a lower risk of major adverse cardiovascular events according to a recent study. Dive into the study's key findings with Dr. John Buse and Dr. Steven Nissen, who published the placebo-controlled study of bempedoic acid among statin-intolerant patients in The New England Journal.

Host: John Buse, MD, PhD Guest: Elizabeth Selvin, PhD, MPH As obesity rates continue to rise in adults with type 1 diabetes, what can we do to combat this growing obstacle? Dr. John Buse speaks with an expert in the field, Dr. Elizabeth Selvin, about obesity in patients with type 1 diabetes and shares management strategies.

Host: John Buse, MD, PhD Guest: Ania Jastreboff, MD, PhD Counseling patients with obesity who are on GLP-1 receptor agonists can be challenging. How can we leverage the biology of GLP-1 receptor antagonists to improve weight loss while avoiding side effects? Dr. John Buse speaks with a leading expert in the field, Dr. Ania Jastreboff, about the role of GLP-1 receptor agonists in weight loss.

Host: John Buse, MD, PhD Guest: Jennifer B. Green, MD The COORDINATE Study evaluated patients with cardiovascular disease and type 2 diabetes who encounter barriers in receiving newer diabetes medications. To better understand these gaps in care, Dr. John Buse speaks with one of the researchers, Dr. Jennifer Green from Duke University in Durham, North Carolina.

Host: John Buse, MD, PhD Guest: Abbie E. Smith-Ryan, PhD, CSCS*D, FNSCA There are immeasurable benefits to exercise, but the hard part for patients may be getting started. How can we help our patients make exercise a part of their lives? Dr. John Buse speaks with Dr. Abbie Smith-Ryan, a Professor of Exercise Physiology at the University of North Carolina – Chapel Hill, about the key benefits of exercise and how to encourage them for various patient populations.

Host: John Buse, MD, PhD Guest: Sue Pedersen, MD, FRCPC New guidelines published by Obesity Canada take a deep dive into pharmacotherapy and feature the latest recommendations on comorbidities and decision tools. To better understand the impact of these guidelines, Dr. John Buse speaks with one of the guidelines authors, Dr. Sue Pedersen, a specialist in endocrinology and metabolism.

Host: John Buse, MD, PhD Guest: Silva Arslanian, MD New research on once-daily semaglutide for adolescent patients with obesity may alter clinicians' approach to care. What do we need to know? Dr. John Buse speaks with one of the study's investigators, Dr. Silva Arslanian, from the University of Pittsburgh to dive into this clinical data and explore how these results may change the treatment landscape.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Zobair M Younossi MD, MPH, FACP, FACG, AGAF, FAASLD Guest: Scott D. Isaacs, MD FACP, FACE Recently, the American Association of Clinical Endocrinology and the American Association for the Study of Liver Diseases released guideline updates on nonalcoholic steatohepatitis (NASH). How will these updates impact clinical practice? Drs. Zobair M.Younossi and Scott D. Isaacs join Dr. Charles Turck to share their insights on these updated guidelines.

Host: John Buse, MD, PhD Guest: Jennifer B. Green, MD What does the latest research on glycemia reduction show us about the impact of glucose-lowering medication in combination with metformin on microvascular and cardiovascular outcomes in patients with type 2 diabetes? Dr. John Buse speaks with one of the study's investigators, Dr. Jennifer Green, a Professor of Medicine at Duke University, about this emerging data.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kenneth Cusi, MD, FACP, FACE Not only is nonalcoholic steatohepatitis (NASH) the most common chronic liver condition worldwide, but it's also becoming the number one cause of liver transplantation beyond hepatitis C. And with its growing prevalence and burden having no end in sight, Dr. Charles Turck speaks with Dr. Kenneth Cusi about how we can better recognize the symptoms of NASH in high-risk patient groups.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kenneth Cusi, MD, FACP, FACE Not only is nonalcoholic steatohepatitis (NASH) the most common chronic liver condition worldwide, but it's also becoming the number one cause of liver transplantation beyond hepatitis C. And with its growing prevalence and burden having no end in sight, Dr. Charles Turck speaks with Dr. Kenneth Cusi about how we can better recognize the symptoms of NASH in high-risk patient groups.

The global epidemic of diabetes and prediabetes afflicts more than 1 billion people.The global epidemic of diabetes and prediabetes afflicts more than 1 billion people. Sadly, more than 50% of people with diabetes do not achieve their desired glucose control. Moreover, less than 25% achieve their blood pressure, cholesterol, and glucose goals.In his book, Conquer Your Diabetes: Prevention, Control, Remission, Dr. Martin Abrahamson and his co-author Sanjiv Chopra, MD put all the pieces of the diabetes puzzle together, including a concise history of the disease, underlying types and causes, prediabetes, obesity, weight loss, pregnancy, mental health, type 2 diabetes prevention and remission, and latest treatments.Dr. Abrahamson joins us today to tell us more about his book & his diabetes research. He is an Associate Professor of Medicine at Harvard Medical School and a previous Chief Medical Officer at Joslin Diabetes Center. He lectures globally on diabetes and has spearheaded educational initiatives on diabetes for physicians around the world.